This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit |  Histology Marketplace:     

Home   History   Meeting Calendar   Career Center   Certification   Contact Us    



2014 nominations are open for the board of directors
Serving on the NSH Board is both challenging and rewarding. It requires a significant commitment; however it is one of the most exceptional learning experiences a person can have. The board's primary objective is to serve the NSH membership and keep our organization moving forward. As such, the NSH board of directors requires candidates who are recognized as excellent leaders with significant knowledge and an ability to think strategically. Click here for Nomination Form and Position Descriptions.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Rare childhood disease may clarify Alzheimer's
Research on a rare childhood disorder may provide clues to understanding and treating more common neurodegenerative diseases like Alzheimer's and Parkinson's. The study, published online in Nature Neuroscience, provides new information about A-T disease, in which children have mutations in both of their copies of the ATM gene and cannot make normal ATM protein. The disorder occurs in an estimated 1 in 40,000 births and leads to problems in movement, coordination, equilibrium and muscle control as well as a number of other deficiencies outside the nervous system. It leaves children unable to walk by adolescence.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Holograms offer hope against malaria
R&D Magazine
Edinburgh scientists have developed a 3-D filming technique that could inform research to stem the spread of malaria. Creating moving digital holograms of malaria sperm has given researchers fresh insights into the behavior of these tiny life forms. Understanding how malaria parasites mate could pave the way for improved prevention and control of this deadly disease, which poses a threat to half of the world's population.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Decoding breast cancer drug resistance
The Scientist
Estrogen is so intimately involved in breast cancer that drugs which disrupt the hormone’s actions have become frontline treatments for the disease. These so-called "hormonal therapies" include tamoxifen and fulvestrant, which directly block the estrogen receptor, and aromatase inhibitors like anastrazole, which prevent the body from making estrogen in the first place. These drugs have been incredibly successful, but for reasons that are still unclear, patients often develop resistance to them, especially when their tumors migrate, or metastasize, to other organs.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  Stellaris RNA FISH Probes

Stellaris RNA FISH is a new research technology that enables direct detection, localization and quantification of RNA. The low cost per assay, simple protocol, and the ability to localize mRNA and lncRNA to organelles and cellular structures provides obvious benefits for life science research. Custom and catalogued probes sets available. MORE

1 dose of HPV vaccine may be enough to prevent cervical cancer
Science Codex
Women vaccinated with one dose of a human papillomavirus vaccine had antibodies against the viruses that remained stable in their blood for four years, suggesting that a single dose of vaccine may be sufficient to generate long-term immune responses and protection against new HPV infections, and ultimately cervical cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
Looking for similar articles? Search here, keyword HPV.

Gene responsible for hereditary cancer syndrome found to disrupt critical growth-regulating pathway
Medical Xpress
Whitehead Institute scientists report that the gene mutated in the rare hereditary disorder known as Birt-Hogg-Dubé cancer syndrome also prevents activation of mTORC1, a critical nutrient-sensing and growth-regulating cellular pathway. This is an unexpected finding, as some cancers keep this pathway turned on to fuel their unchecked growth and expansion. In the case of Birt-Hogg-Dubé syndrome, the mutated gene prevents mTORC1 pathway activation early in the formation of tumors.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Brain tumor drug IDs cancer cells from healthy ones
Drug Discovery & Development
A potential new drug, already in clinical development, can stop brain tumor cells growing while leaving healthy cells alone, according to new research published in PLOS ONE. Cancer Research U.K. scientists from the Samantha Dickson Brain Cancer Unit, which is funded by The Brian Tumor Charity, at the UCL Cancer Institute in London focused on glioblastoma, the most common type of brain tumor. Using cells growing in the lab, they treated glioblastoma cells and healthy cells with more than 150 potential drugs, and compared the responses. One of these molecules, called J101, was able to stop the cancer cells growing but left the normal cells alone.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

ergoCentric Laboratory Seating

Visit LabStorage System’s updated website to view details about this new laboratory seating with specially formulated Infection Control coating. Non-porous and easily disinfected, this moisture proof coating is anti-bacterial, anti-fungal and stain resistant. more
Spring Bioscience - BRAF V600E

Spring Bioscience is leading the research industry by pioneering novel, next generation antibodies that can differentiate mutant and normal protein, enabling pathologists to see relevant mutations within their cellular context. Having already released Exon19 and EGFR L858R for exclusive use by Ventana Medical Systems, Spring Bioscience has launched BRAF V600E.
Click here to find out more.
Reduce Cost with Same Quality

GBI Labs produces the largest selection of secondary detection kits. We provide free samples to 1st time users. Staining with our kits results in similar or better sensitivity than other detection kits on the market. Some 110mL kits cost as little as $700.00 and 18 ml kit > $300.00.

Why tumor cells go on dangerous tours
Science Codex
Tumors become highly malignant when they acquire the ability to colonize other tissues and form metastases. Researchers at Ludwig-Maximilians-Universitaet in Munich have identified a factor that promotes metastasis of colon tumors — and presents a possible target for therapy. The protein c-MYC is referred to as a master regulator because it controls the activity of hundreds of genes, including many that drive cell growth and cell proliferation. Genetic changes that perturb its own regulation therefore have serious consequences for tissue homeostasis, and often result in cancer. Indeed, in most cancers, one finds mutations that hyperactivate the c-MYC gene.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Cutting edge: What's new in pharmaceutical R&D
By Rosemary Sparacio
It is clear that pharmaceutical companies are tackling serious diseases in therapeutic areas that heretofore were more challenging. But new technology has changed that landscape forever. And patients with diseases like cystic fibrosis, cancer, celiac disease and Crohn's disease — just to name a few — now have a wide variety of drugs to look forward to in the near future. Many pharmaceutical companies are forming alliances with significant monetary investments to improve both their product lines and their bottom lines.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Missed last week's issue? See which articles your colleagues read most.

    The NSH 2014 Laboratory Webinar Series now open for registration (NSH)
Alzheimer's study reveals new genes implicated in disease (The Guardian)
Analyzing hundreds of cells in a few mouse clicks (Swiss Federal Institute of Technology in Lausanne via R&D Magazine)
HIV drugs may get new role in fighting cancer (Reuters)

Don't be left behind. Click here to see what else you missed.

BRAF status not associated with negative predictors for papillary thyroid cancer
BRAFV600E mutations were not significantly associated with most clinicopathologic features suggestive of aggressive papillary thyroid carcinoma, according to results of a retrospective study. Researchers pooled data on 429 patients from the pathology archives at the University of California to assess the significance of BRAF V600E mutation in papillary thyroid cancer. Clinicopathologic features in patients with and without BRAF mutations served as the primary outcome measure.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Under the Microscope
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Ashley Whipple, Senior Content Editor, 469.420.2642   
Contribute news

This edition of Under the Microscope was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Recent issues
Nov. 6, 2103
Oct. 30, 2013
Oct. 23, 2013
Oct. 16, 2013

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063